Stay updated with breaking news from Otcmkts ceos. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Psykey, Inc. (OTCMKTS:CEOS – Get Free Report) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 58,400 shares, an increase of 247.6% from the December 31st total of 16,800 shares. Based on an average daily trading volume, of 1,880,300 shares, the days-to-cover ratio […] ....
Psykey, Inc. (OTCMKTS:CEOS – Get Free Report) saw a significant increase in short interest in January. As of January 15th, there was short interest totalling 58,400 shares, an increase of 247.6% from the December 31st total of 16,800 shares. Based on an average daily trading volume, of 1,880,300 shares, the short-interest ratio is currently 0.0 […] ....
Psykey (OTCMKTS:CEOS – Get Free Report) is one of 70 publicly-traded companies in the “Medical Instruments & Supplies” industry, but how does it weigh in compared to its rivals? We will compare Psykey to related companies based on the strength of its earnings, valuation, profitability, analyst recommendations, risk, institutional ownership and dividends. Profitability This table […] ....
Psykey (OTCMKTS:CEOS – Get Free Report) is one of 83 publicly-traded companies in the “Medical Instruments & Supplies” industry, but how does it contrast to its peers? We will compare Psykey to similar businesses based on the strength of its earnings, analyst recommendations, risk, profitability, institutional ownership, dividends and valuation. Analyst Recommendations This is a […] ....
Psykey (OTCMKTS:CEOS – Get Free Report) and Repligen (NASDAQ:RGEN – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Valuation & Earnings This table compares Psykey and Repligen’s revenue, […] ....